| 1 |
Dogruel H, Balci MK. Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist's role intreatment; from the past to future [J]. World J Diabetes, 2019, 10(8): 446-453.
|
| 2 |
Brunetti A, Chiefari E, Foti D. Recent advances in the molecular genetics of type 2 diabetes mellitus [J]. World J Diabetes, 2014, 5(2): 128-140.
|
| 3 |
Harding JL, Pavkov ME, Magliano DJ, et al. Global trends in diabetes complications: a review of current evidence [J]. Diabetologia, 2019, 62(1): 3-16.
|
| 4 |
Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: the last ten years [J]. Cell, 2012, 148(6): 1160-1171.
|
| 5 |
Hotamisligil GS. Endoplasmic reticulum stress and inflammation in obesity and type 2 diabetes [J]. Novartis Found Symp, 2007, 286: 86-94; discussion 94-98, 162-3, 196-203.
|
| 6 |
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes [J]. Nature, 2006, 444(7121): 840-846.
|
| 7 |
Hotamisligil GS. Inflammation and metabolic disorders [J]. Nature, 2006, 444(7121): 860-867.
|
| 8 |
Andronescu CI, Purcarea MR, Babes PA. Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications [J]. J Med Life, 2018, 11(1): 20-23.
|
| 9 |
Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis [J]. N Engl J Med, 2017, 377(21): 2063-2072.
|
| 10 |
Funke A, Schreurs M, Aparicio-Vergara M, et al. Cholesterol-induced hepatic inflammation does not contribute to the development of insulin resistance in male LDL receptor knockout mice [J]. Atherosclerosis, 2014, 232(2): 390-396.
|
| 11 |
Petersen MC, Shulman GI. Roles of diacylglycerols and ceramides in hepatic insulin resistance [J]. Trends Pharmacol Sci, 2017, 38(7): 649-665.
|
| 12 |
Conway G, Dewailly D, Diamanti-Kandarakis E, et al. European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS special interest group's questionnaire [J]. Eur J Endocrinol, 2014, 171(4): 489-498.
|
| 13 |
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications [J]. Endocr Rev, 2012, 33(6): 981-1030.
|
| 14 |
Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences [J]. Metabolism, 2018, 86: 33-43.
|
| 15 |
Vassilatou E, Lafoyianni S, Vryonidou A, et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome [J]. Hum Reprod, 2010, 25(1): 212-220.
|
| 16 |
Macut D, Tziomalos K, Božić-Antić I, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome [J]. Hum Reprod, 2016, 31(6): 1347-1353.
|
| 17 |
Petta S, Ciresi A, Bianco J, et al. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS [J]. PLoS One, 2017, 12(11): e0186136.
|
| 18 |
Wu J, Yao XY, Shi RX, et al. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis [J]. Reprod Health, 2018, 15(1): 77.
|
| 19 |
Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome [J]. World J Gastroenterol, 2014, 20(26): p 8351-8563.
|
| 20 |
Macut D, Bjekić-Macut J, Livadas S, et al. Nonalcoholic fatty liver disease in patients with polycystic ovary syndrome [J]. Curr Pharm Des, 2018, 24(38): 4593-4597.
|
| 21 |
Vestal DJ, Buss JE, McKercher SR, et al. Murine GBP-2: a new IFN-gamma-induced member of the GBP family of GTPases isolated from macrophages [J]. J Interferon Cytokine Res, 1998, 18(11): 977-985.
|
| 22 |
Decker T, Lew DJ, Cheng YS, et al. Interactions of alpha- and gamma-interferon in the transcriptional regulation of the gene encoding a guanylate-binding protein [J]. EMBO J, 1989, 8(7): 2009-2014.
|
| 23 |
Boehm U, Guethlein L, Klamp T, et al. Two families of GTPases dominate the complex cellular response to IFN-gamma [J]. J Immunol, 1998, 161(12): 6715-6723.
|
| 24 |
Meunier E, Wallet P, Dreier RF, et al. Guanylate-binding proteins promote activation of the AIM2 inflammasome during infection with Francisella novicida [J]. Nat Immunol, 2015, 16(5): 476-484.
|
| 25 |
Man SM, Place DE, Kuriakose T, et al. Interferon-inducible guanylate-binding proteins at the interface of cell-autonomous immunity and inflammasome activation [J]. J Leukoc Biol, 2017, 101(1): 143-150.
|
| 26 |
Christian SL, Zu D, Licursi M, et al. Suppression of IFN-induced transcription underlies IFN defects generated by activated Ras/MEK in human cancer cells [J]. PLoS One, 2012, 7(9): e44267.
|
| 27 |
Rahvar F, Salimi M, Mozdarani H. Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer [J]. Genet Mol Biol, 2020, 43(4): e20190230.
|
| 28 |
Yu S, Yu X, Sun L, et al. GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway [J]. Oncogene, 2020, 39(27): 5042-5055.
|
| 29 |
Basu S, Murphy ME. Genetic modifiers of the p53 pathway [J]. Cold Spring Harb Perspect Med, 2016, 6(4): a026302.
|
| 30 |
Vousden KH, Prives C. Blinded by the light: the growing complexity of p53 [J]. Cell, 2009, 137(3): 413-431.
|
| 31 |
Goel P, Manning JA, Kumar S. NEDD4-2 (NEDD4L): the ubiquitin ligase for multiple membrane proteins [J]. Gene, 2015, 557(1): 1-10. d
|
| 32 |
Dunn DM, Ishigami T, Pankow J, et al. Common variant of human NEDD4L activates a cryptic splice site to form a frameshifted transcript [J]. J Hum Genet, 2002, 47(12): 665-676.
|
| 33 |
Russo CJ, Melista E, Cui J, et al. Association of NEDD4L ubiquitin ligase with essential hypertension [J]. Hypertension, 2005, 46(3): 488-491.
|
| 34 |
Svensson-Färbom P, Wahlstrand B, Almgren P, et al. A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients [J]. J Hypertens, 2011, 29(2): 388-395.
|
| 35 |
Duerr J, Leitz DHW, Szczygiel M, et al. Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice [J]. Nat Commun, 2020, 11(1): 2012.
|
| 36 |
Song R, Peng W, Zhang Y, et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders [J]. Nature, 2013, 494(7437): 375-379.
|
| 37 |
Cao XR, Lill NL, Boase N, et al. Nedd4 controls animal growth by regulating IGF-1 signaling [J]. Sci Signal, 2008, 1(38): ra5.
|
| 38 |
Li JJ, Ferry RJJr, Diao S, et al. Nedd4 haploinsufficient mice display moderate insulin resistance, enhanced lipolysis, and protection against high-fat diet-induced obesity [J]. Endocrinology, 2015, 156(4): 1283-1291.
|
| 39 |
Ranza E, Guimier A, Verloes A, et al. Overlapping phenotypes between SHORT and Noonan syndromes in patients with PTPN11 pathogenic variants [J]. Clin Genet, 2020, 98(1): 10-18.
|